Citi raised the firm’s price target on Allogene Therapeutics to $8 from $7 and keeps a Buy rating on the shares post the Q2 report. Allogene continues to make steady progress advancing its realigned pipeline, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLO:
- Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
- Allogene Therapeutics reports Q2 EPS (35c), consensus (35c)
- Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update
- Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update
- JMP Securities healthcare analysts hold an analyst/industry conference call